EGFR gene mutation detection primer probe and its kit

Abstract

The invention relates to an EGFR gene mutation detection primer probe and a kit thereof. The kit comprises a digital PCR master mix used for preparing digital PCR reaction liquor, a liquid droplet stabilizer and primer probe mixed liquor. The primer probe mixed liquor comprises an upstream primer a, a downstream primer a, a deficiency probe a and a detection probe a, wherein the upstream primer a, the downstream primer a, the deficiency probe a and the detection probe a are used for detecting 19 exon E19-Dels locus; the primer probe mixed liquor further comprises a mutation upstream primer b, a mutation probe b, a wild upstream primer b, a wild probe b, and an universal downstream primer b, wherein the mutation upstream primer b, the mutation probe b, the wild upstream primer b, the wild probe b and the universal downstream primer b are used for detecting a 20 exon T790M locus; the primer probe mixed liquor further comprises a mutation upstream primer c, a mutation probe c, a wild upstream primer c, a wild probe c and an universal downstream primer c, wherein the mutation upstream primer c, the mutation probe c, the wild upstream primer c, the wild probe c and the universal downstream primer c are used for detecting 21 exon L858R locus. The EGFR gene mutation detection kit is capable of quickly, conveniently and accurately detecting situations of EGFR gene mutation in a patient with non-small cell lung cancer.

Description

technical field [0001] The invention relates to a primer, a probe and a detection product for detecting EGFR gene mutation, belonging to the field of biotechnology. Background technique [0002] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, and afatinib have demonstrated significant efficacy in patients with advanced non-small cell lung cancer with activating mutations in EGFR, EGFR -TKI has become a milestone in the treatment of non-small cell lung cancer. However, almost all patients who initially respond well to EGFR-TKI will develop drug resistance and disease progression within 6-12 months, which is called "acquired drug resistance". Many studies have confirmed that the mutation status of EGFR determines the tumor response to EGFR-TKI. Therefore, EGFR mutation detection before treatment to screen patients with indications for EGFR-TKIs treatment, continuous detection of changes in mutation status during treatment, and ...

AI Technical Summary

Problems solved by technology

[0005] Exploring the mechanism of EGFR-TKI drug resistance and predicting the prognosis of patients has become a feasible way. However, due to the low content of cfDNA in most people's serum / plasma and relatively small cfDNA fragments, the current clinical detection of EGFR is mainly by sequencing and ARMS. law, does not apply

Images